Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc. (NKTX)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad acc
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta (NASDAQ:NKTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NKTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason [Seeking Alpha]Seeking Alpha
- Nkarta (NASDAQ:NKTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NKTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
- Nkarta (NASDAQ:NKTX) had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights GlobeNewswire
NKTX
Earnings
- 11/10/25 - Beat
NKTX
Analyst Actions
- 11/11/25 - Stifel
NKTX
Sec Filings
- 11/24/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- NKTX's page on the SEC website